Exploring changes in metabolites in nasopharyngeal carcinoma patients

A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites During the Occurrence and Development of Nasopharyngeal Carcinoma in Southern China.

This study looks at how certain substances in the blood and urine change in people with nasopharyngeal carcinoma and those with the EBV virus to see if these changes can help us understand the disease better.

Quick facts

• Study type: Observational
• Enrollment: 2000 (estimated)
• Ages: 18 Years to 70 Years
• Sex: All
• Sponsor: Nanfang Hospital, Southern Medical University (Academic / other)
• Locations: 1 site (Guangzhou, Guangdong)
• Trial ID: NCT05682703 on ClinicalTrials.gov

What this trial studies

This observational study investigates the dynamic changes of plasma and urine metabolites in patients with nasopharyngeal carcinoma and those infected with the EBV virus. By utilizing proteomics technology and liquid biopsy, the study aims to understand how these metabolites vary at different stages of the disease. The research focuses on the relationship between metabolite changes and the clinical progression of nasopharyngeal carcinoma, providing insights into its complex transformation process.

Who should consider this trial

Good fit: Ideal candidates include patients diagnosed with nasopharyngeal carcinoma, individuals with EBV infection, and healthy individuals without related diseases.

Not a fit: Patients with a history of non-research related liver diseases or other conditions affecting blood metabolism may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance the understanding of nasopharyngeal carcinoma progression and lead to improved diagnostic and therapeutic strategies.

How similar studies have performed: While the approach of using metabolite analysis in cancer research is established, the specific focus on nasopharyngeal carcinoma and its dynamic changes is relatively novel.

Eligibility criteria

Inclusion Criteria:

* EBV virus infector: QPCR/EBV antibody, diagnosed as EBV infection patient with previous infection;
* Nasopharyngeal carcinoma patients:Patients diagnosed as nasopharyngeal carcinoma by pathological diagnosis (2018 WHO standard);
* Healthy people: Healthy people who have no history of nasopharynx related diseases or other known diseases that may affect blood lipid/protein metabolism and have been hospitalized in the Physical Examination Center of Southern Hospital.

Exclusion Criteria:

1. People who have a history of non research related liver diseases or other diseases known to affect blood metabolism (except for controlled type II diabetes);
2. Have a history of other malignant tumors, except for fully treated basal cell carcinoma or squamous cell carcinoma and cervical carcinoma in situ;
3. Diseases requiring long-term use of immunosuppressive drugs (including steroids), including but not limited to congenital or acquired immunodeficiency diseases or active central nervous system metastatic cancer, active infection or uncontrolled heart disease;
4. Suffer from other uncontrolled serious diseases at the same time, such as unstable heart disease requiring treatment, diabetes with unsatisfactory control (fasting blood glucose\>1.5 × Upper limit of normal value), mental illness and severe allergic history.
5. BMI is less than 18 or more than 25. -

Where this trial is running

Guangzhou, Guangdong

• Southern medical university — Guangzhou, Guangdong, China (Recruiting)

Study contacts

• Principal investigator: jian guan, MD — Nanfang Hospital, Southern Medical University
• Study coordinator: jian guan, MD

Conditions Nasopharyngeal Carcinoma; EBV Infection